Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Price
Data
About
MRK stock price forecast
News
Competitors
Tokenization
Crypto
FAQ
Merck & Company, Inc. stock logo

Merck & Company, Inc.

MRK·NYSE

Last updated as of 2026-02-27 10:54 EST. Stock price information is sourced from TradingView and reflects real-time market prices.

Insights
Calculator
News

MRK stock price change

On the last trading day, MRK stock closed at 122.46 USD, with a price change of -1.19% for the day.
Trade stock perps

About Bitget

The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more

MRK key data

Previous close122.46 USD
Market cap303.95B USD
Volume11.08M
P/E ratio16.83
Dividend yield (TTM)2.65%
Dividend amount0.85 USD
Last ex-dividend dateDec 15, 2025
Last payment dateJan 08, 2026
EPS diluted (TTM)7.28 USD
Net income (FY)18.25B USD
Revenue (FY)65.01B USD
Next report dateApr 30, 2026
EPS estimate-
Revenue estimate15.97B USD USD
Shares float2.48B
Beta (1Y)0.51
Tokenized stocks

Have you heard of stock tokens?

A new way to trade stocks — anytime, anywhere, 24/7.

Learn more

Merck & Company, Inc. overview

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.
Sector
Health technology
Industry
Pharmaceuticals: Major
CEO
Robert M. Davis
Headquarters
Rahway
Website
merck.com
Founded
1891
Employees (FY)
-
Change (1Y)
-
Revenue / Employee (1Y)
-
Net income / Employee (1Y)
-

MRK Pulse

Daily updates on MRK stock prices, fund flows, and market news, generated by AI and reviewed by our team of analysts. Always DYOR.

• MRK Stock Price 24h change: -1.10%. From 123.82 USD to 122.46 USD. The slight decline followed a strong recent rally and reflects a cooling period as investors digest the company's major organizational restructuring and long-term patent cliff risks.
• From a technical perspective, MRK remains in a "long-term bullish" phase, trading consistently above its 200-day moving average (96.81 USD). However, short-term indicators such as the 14-day RSI (45.06) and a downward move below the 5-day moving average (122.67 USD) suggest a neutral to bearish consolidation phase.
• Merck announced a major restructuring of its Human Health division into two distinct units—Oncology and Specialty Pharma—to maximize growth ahead of the 2028 patent expiration for its blockbuster drug, Keytruda.
• Royal Bank of Canada (RBC) upgraded Merck to "Moderate Buy" with a price target of 125.88 USD, citing positive late-stage clinical data for its HIV regimen and pediatric RSV treatments.
• Merck Animal Health received FDA approval for NUMELVI™, the first second-generation JAK inhibitor for treating allergic dermatitis in dogs, expanding its diversified revenue streams.
• The U.S. FDA accepted Teva Pharmaceuticals' New Drug Application for a once-monthly long-acting injectable treatment for schizophrenia, highlighting the sector's focus on long-term drug delivery innovations.
• Global pharmaceutical markets are seeing increased regulatory scrutiny as the UK's MHRA and other agencies intensify safety audits and crack down on non-compliant drug manufacturing standards.
See more
about 23h ago
• MRK Stock Price 24h change: +0.20%. From 123.82 USD to 124.10 USD (as of Feb 24, 2026 closing). The slight gain reflects positive sentiment following a major human health organizational restructuring despite recent cautious 2026 guidance.
• From a technical perspective, MRK exhibits a strong bullish trend, trading above its 50-day ($111.13) and 200-day ($96.33) moving averages. The RSI is in the upper-neutral zone (~63), and the stock recently hit a 52-week high, though it faces immediate resistance near $124.84 with support established at $120.42.
• Merck announced a strategic reorganization of its Human Health division into two distinct units—Oncology and Specialty—to streamline operations and prepare for the 2028 patent expiration of its top-selling drug, Keytruda.
• RBC Capital initiated coverage of Merck with an "Outperform" rating and a $142 price target, citing high visibility into the pipeline and potential for significant Phase 3 readouts in immunology and oncology throughout 2026.
• Merck released positive Phase 3 data for Enflonsia, its RSV treatment for infants, showing sustained efficacy over two respiratory seasons, which supports potential label expansion and long-term revenue diversification.
• The U.S. pharmaceutical sector is facing increased political scrutiny as the administration considers sector-specific tariffs to enforce "most-favored-nation" drug pricing, creating broad regulatory uncertainty for major drugmakers.
• Industry-wide M&A activity remains robust as biotech firms seek partnerships to fuel drug discovery; recently, BahiaFarma, Biocon Biologics, and Bionovis signed a memorandum of understanding to co-develop oncology biologics.
See more
about 1D ago

MRK stock price forecast

According to technical indicators for MRK stock, the price is likely to fluctuate within the range of 137.13–140.97 USD over the next week. Market analysts predict that the price of MRK stock will likely fluctuate within the range of 127.37–147.49 USD over the next months.

Based on 1-year price forecasts from 70 analysts, the highest estimate is 242.85 USD, while the lowest estimate is 120.62 USD.

For more information, please see the MRK stock price forecast page.

Latest MRK stock news

Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

101 finance2026-02-23 11:51:12

Merck & Co., Inc. recently announced a significant executive appointment

老虎证券2026-02-23 11:56:00

Merck's Strategic Shift Signals New Growth Horizons

Finviz2026-02-23 14:18:12

Barclays Highlights Merck's (MRK) Pipeline Catalysts in Coverage Initiation

Finviz2026-02-23 18:15:41

Tectonic Therapeutic Appoints Francois Nader, M.D., as Chair and Independent Director of the Board

Finviz2026-02-23 21:03:44

Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA

Finviz2026-02-23 21:33:12

Merck (MRK) Announces Positive Phase 3 SMART Trial Results for ENFLONSIA (Clesrovimab)

Finviz2026-02-24 07:12:42

SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus

Finviz2026-02-24 17:39:42

How Does Merck & Co.'s Stock Performance Stack Up Against Other Companies in the Healthcare Sector?

101 finance2026-02-24 19:12:38

Is Johnson & Johnson Able to Maintain Its Strong Double-Digit Growth in Oncology?

101 finance2026-02-25 14:57:58

Merck & Co. announced that its application submitted under the Prescription Drug User Fee Act has received a target action date from the U.S. Food and Drug Administration—April 28, 2026.

老虎证券2026-02-25 17:59:01

Merck announced groundbreaking data from three Phase III clinical trials at the CROI 2026 conference.

老虎证券2026-02-25 18:00:06

RBC Capital Sees Merck (MRK) Returning to Growth Sooner Than Market Expects

Finviz2026-02-26 02:51:37

OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

Finviz2026-02-26 21:09:42

BMY's Stock Slumps 0.33% Despite Strong Clinical Data, Trading Volume Ranks 201st

101 finance2026-02-26 23:24:44

With just a Bitget account, you can trade stocks and cryptocurrencies at the same time.

Join now!

FAQ

What is the stock price of Merck & Company, Inc.?

MRK is currently priced at 122.46 USD — its price has changed by -1.19% over the past 24 hours. You can track the stock price performance of Merck & Company, Inc. more closely on the price chart at the top of this page.

What is the stock ticker of Merck & Company, Inc.?

Depending on the exchange, the stock ticker may vary. For instance, on NYSE, Merck & Company, Inc. is traded under the ticker MRK.

What is the stock forecast of MRK?

We've gathered analysts' opinions on Merck & Company, Inc.'s future price. According to their forecasts, MRK has a maximum estimate of 1224.60 USD and a minimum estimate of 244.92 USD.

What is the market cap of Merck & Company, Inc.?

Merck & Company, Inc. has a market capitalization of 303.95B USD.

What is P/E ratio (TTM)?

The P/E ratio (TTM) stands for price-to-earnings ratio (trailing twelve months). It is a historical valuation metric calculated using a company's earnings per share (EPS) over the most recent twelve consecutive months, reflecting the company's past profitability.

The P/E ratio measures the relationship between a stock's price and a company's profitability, and is often used as a basis for judging whether a stock is "cheap" or "expensive."

P/E ratio = market price (P) ÷ earnings per share (EPS), or P/E ratio = total market capitalization ÷ net profit attributable to shareholders

The interpretation of the P/E ratio (TTM) should always be considered alongside other factors and is mainly used for valuation comparisons rather than as a standalone indicator.

  • A lower P/E ratio (TTM) means investors are paying less for each unit of earnings. This may indicate that the stock is undervalued, or that the market has limited expectations for the company's future growth, such as in mature or slow-growing industries.
  • A higher P/E ratio (TTM) means investors are paying more for each unit of earnings. This often reflects expectations of strong future earnings growth, which is common among growth or technology stocks, though it may also suggest the stock is overvalued.
  • Comparison with peers: Compare the company's P/E (TTM) with the average or median P/E of other companies in the same industry. A significantly higher P/E may require further analysis to determine whether the company's high valuation is justified by stronger growth prospects or competitive advantages.
  • Comparison with historical levels: Compare the company's current P/E (TTM) with its own historical average (such as over the past 5 or 10 years) to assess whether the current valuation is at a historical high or low.
  • Comparison with the broader market: Compare the company's P/E (TTM) with major market indices (such as the S&P 500) to see how the market is valuing the company overall.

P/E ratios can vary widely across industries, and there is no single "ideal" P/E level. A reasonable P/E range depends on the industry, the company's growth potential, and the broader macroeconomic environment. Investment decisions should not rely solely on the P/E ratio (TTM) but should be based on a comprehensive analysis that includes company quality, growth prospects, and financial health.

Can I trade stocks on Bitget?

You can trade stocks on Bitget, but mainly through stock tokens and stock perps, rather than by directly buying or selling traditional stocks.

This approach reflects Bitget's vision as a Universal Exchange (UEX), designed to connect traditional financial markets with cryptocurrency markets.

Bitget currently offers the following stock-related trading formats:

1. Stock tokens (spot)

Nature: Stock tokens are digital tokens pegged to the price of specific traditional stocks (such as TSLAUSDT and NVDAUSDT) and are traded on Bitget's spot market.

Features: When you trade stock tokens, you are buying and holding tokens rather than owning the underlying traditional stocks.

  • The price of these tokens generally follows the price movements of the stocks they are pegged to, such as Tesla or Nvidia.
  • The advantage is that you can participate in the price movements of traditional financial assets, such as U.S. stocks, using cryptocurrencies (for example, USDT), without the need for a traditional brokerage account.

2. Stock perps

Nature: Bitget also offers USDT-margined perpetual futures, commonly referred to as stock perps, based on major U.S. blue-chip stocks such as Tesla and Meta.

Characteristics: Stock perps are derivative products that allow you to take a bullish or bearish view on the future price of an underlying stock through margin trading. These products typically support leverage, such as up to 25x.

It does not involve owning the underlying stock. Instead, profits and losses are settled based on price movements of the futures.

Important note: When trading stock perps on Bitget, you are participating in derivative markets within the cryptocurrency ecosystem. This is fundamentally different from purchasing publicly traded shares through a traditional brokerage, as you do not own equity in the underlying company.

Futures trading and the use of leverage involve high risk. Please ensure you fully understand the risks before trading.

If you wish to directly hold equity in traditional stocks and enjoy shareholder rights (such as receiving dividends), you must trade through a regulated traditional securities brokerage or brokerage platform.

What are the advantages of Bitget's stock perps?

Bitget's stock perps—typically perpetual futures based on stock token prices—are an innovative offering that allows cryptocurrency platforms to provide exposure to traditional financial markets.

Compared to traditional stock or futures trading, they offer several unique advantages, primarily due to the platform's trading infrastructure.

Bitget's stock perps, typically USDT-denominated derivatives, offer the following key advantages:

1. Trading convenience and global accessibility

  • 24/7 trading: Traditional stock markets, such as U.S. equity markets, operate during fixed trading hours. In contrast, cryptocurrency derivatives markets are typically open 24/7. This means investors can trade anytime, capitalizing on breaking news or market fluctuations.
  • Lower entry barriers and faster onboarding: Compared with traditional brokerages, which often require extensive identity verification and lengthy account setup processes, Bitget generally offers faster account onboarding. Users can trade using cryptocurrencies such as USDT, without the need for complex fiat deposit and withdrawal procedures.
  • Global accessibility: Users can access derivatives trading linked to globally recognized stocks via the Bitget platform, subject to applicable regulations.

2. Capital efficiency and high leverage

  • High leverage options: Stock perps typically offer higher leverage than traditional stock trading (for example, up to 25x). This allows traders to control larger positions with smaller margin requirements, improving capital efficiency.
    Note: While high leverage can amplify gains, it also amplifies losses proportionally.
  • Two-way trading: Traders can easily take both long and short positions. This means traders can potentially profit from market volatility whether stock prices rise or fall, provided the market direction is correctly anticipated.

3. Trading and settlement using cryptocurrency

  • USDT margin: Stock perps on Bitget typically use USDT (or other stablecoins) as the margin and settlement currency. For users who already hold cryptocurrency, there is no need to convert assets into fiat currency, allowing them to trade directly with stablecoins.
  • Efficient fund transfers: Crypto-based transfers and settlements are typically faster than traditional fiat systems, enabling more efficient global fund allocation.

4. Integration

One-stop platform: Bitget allows users to trade spot cryptocurrencies, crypto derivatives, and stock perps on a single platform, making it easier to manage different asset types in one place.

Risk warning:

While Bitget's stock perps offer several advantages, it is important to understand the associated risks.

  • High leverage risk: Leveraged trading can result in rapid loss of your entire margin.
  • No equity ownership: When trading stock perps, you do not own the underlying shares. As a result, you are not entitled to dividends or voting rights.
  • Market liquidity risk: Stock token perps may have lower liquidity than their counterparts in traditional stock markets, especially outside regular trading hours.

In summary, Bitget's stock perps offer advantages such as greater trading flexibility, lower entry barriers, and higher capital efficiency.

What are the trading fees for Bitget stock perps?

Trading fees for Bitget stock perps (USDT-margined perpetual futures) mainly include transaction fees and funding rates.

Transaction fees:

Bitget offers limited-time fee promotions for stock perps (especially stock token perps) from time to time to attract traders.

Standard reference rates: Under Bitget's standard futures fee structure, the taker fee is typically around 0.06%, while the maker fee is around 0.02%.

Current promotions for stock perps (important): To promote its stock perps products, Bitget is offering discounted transaction fees during Q4 2025, with taker fees as low as 0.006% and maker fees as low as 0.002%. There is also a limited-time promotion offering zero-fee trading for spot stock tokens.

Recommendation: Since promotional activities are subject to change or end at any time, please visit Bitget's official Fee overview or Announcement Center page for the latest and most accurate rates at the time of trading.

Funding rate:

The funding rate is a key mechanism in perpetual futures (including stock perps) that helps keep the futures price closely aligned with the spot price of the underlying asset. It is not a fee charged by the platform, but a periodic payment exchanged between long and short traders.

Funding rates fluctuate dynamically and are mainly driven by market sentiment and imbalances between long and short positions. Stock perps generally experience lower volatility than cryptocurrencies, so funding rates are often relatively low during stable market conditions. However, during earnings seasons or major positive or negative news events, heavy concentration of long or short positions—such as in high-growth technology stocks like Tesla or Nvidia—can create significant imbalances, causing funding rates to spike in the short term.

Funding payments are typically settled every 8 hours. If you close your position before the funding settlement time, no funding payment will be charged or received.

Funding rates are not fixed. If you hold a position for an extended period, high positive funding rates (for long positions) or high negative funding rates (for short positions) will affect your overall holding costs or potential returns. For this reason, it is important to monitor the funding rate in real time on the trading interface.

NYSE/
MRK